Another gubernatorial veto has stalled the launch of a legal retail cannabis market in Virginia for a further year. For cultivators, distributors and entrepreneurs the immediate effect is prolonged uncertainty around licences, real‑estate and capital deployment; for consumers the options remain limited. This analysis explains the commercial implications and what industry actors should watch next.

Researchers at Yale School of Medicine report that the genetic architecture associated with trying or using cannabis diverges from the genetics linked to problematic use and addiction. For industry professionals, breeders and medical suppliers the distinction matters for research priorities, product development and public-health engagement.

The Psychiatric Times has highlighted connections between cannabis policy and psychiatric health. For industry professionals, regulators and clinical services, the consequences are practical rather than purely legal: changes in access, product quality, criminalisation and health-service demand can all alter psychiatric risk and care pathways. This editorial separates what the original piece asserts from areas of uncertainty and outlines what different actors in the sector should be watching.